ARCHIVES

CMS Looks At Coverage of Two Agents Approved on Surrogate Endpoints

This article is from The Cancer Letter archive.

Vol. 29 No. 08 | February 21, 2003

Download PDF Visit The Full Archive

Related Articles

Five-year Childhood ALL Survival Increased To 90.4 Percent by 2005

March 30, 2012

NIH News: Varmus Presents “Modest Proposal for a Simpler NIH”

August 6, 1999

NCI To Fund Partnerships Between Cancer Centers and Minority Institutions

November 12, 1999

FDA Approves Arranon For Leukemia And Lymphoma

December 30, 2005

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

November 26, 2010

Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment

February 7, 2014